Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution

Pamela Blair Allen, MD, Mary Ellen Pavone, MD, Kristin M Smith, R.N., Ralph Kazer, MD, Alfred W Rademaker, PhD, Angela K Lawson, MD, Molly Moravek, MD, Rafael Confino, Jr., Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2015) 126 (23): 2111.

https://doi.org/10.1182/blood.V126.23.2111.2111

Published: 2015

Journal Articles

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

Ji Heon (Paul) Lee, MDPhD, Alfred W. Rademaker, PhD, Bayard L. Powell, MD, Susan Geyer, PhD, Richard A. Larson, John Gregory, MD, Nobuko Hijiya, MD, James H. Feusner, MD

Blood (2014) 124 (21): 957.

https://doi.org/10.1182/blood.V124.21.957.957

Published: 2014

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

June M. McKoy, MD, JD, MPH, MBA, Dustin B Liebling, BA, Alfred W. Rademaker, PhD, Bing Bing Weitner, MS, Beatrice J. Edwards, MD, MPH, Steven M. Belknap, MD, Andrew Thurston, MD, Monica Boen, MD, Katrina-Marie E Tulas, BA, Judith M McKoy-Bent, BA, BSN, Jowella Pineda, MD, Dennis P. West, PhD

Blood (2012) 120 (21): 4692.

https://doi.org/10.1182/blood.V120.21.4692.4692

Published: 2012

Journal Articles

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Ryan D. Gentzler, MD, MS, Andrew M. Evens, DO, MSc, Alfred W. Rademaker, PhD, Bharat B Mittal, M.D., Adam M. Petrich, MD, Jessica K. Altman, MD, Olga Frankfurt, MD, Daina Variakojis, MD, Seema Singhal, M.D., Jayesh Mehta, MD, Joel R Green, MD, Stephanie Williams, MD, Lynne Kaminer, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2024.

https://doi.org/10.1182/blood.V120.21.2024.2024

Published: 2012

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Adi Gidron, MD, John Eklund, MD, Brenda Martone, RN, MSN, Alfred W. Rademaker, PhD, Charles Goolsby, PhD, Laura Marszalek, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 1729.

https://doi.org/10.1182/blood.V108.11.1729.1729

Published: 2006

NARROW

Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Email alerts

ASH Publications

American Society of Hematology

Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only